47,885 Shares in XBiotech Inc. $XBIT Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in XBiotech Inc. (NASDAQ:XBIT) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 47,885 shares of the biopharmaceutical company’s stock, valued at approximately $142,000. Y Intercept Hong Kong Ltd owned 0.16% of XBiotech at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in XBIT. Hsbc Holdings PLC acquired a new stake in shares of XBiotech during the first quarter worth $52,000. Nuveen LLC acquired a new position in shares of XBiotech in the first quarter valued at about $81,000. Charles Schwab Investment Management Inc. increased its position in XBiotech by 15.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 8,918 shares during the period. Finally, Bank of America Corp DE raised its stake in XBiotech by 42.0% in the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 5,887 shares in the last quarter. Institutional investors own 55.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XBiotech in a research report on Wednesday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

XBiotech Stock Down 2.1%

XBIT stock opened at $2.34 on Monday. The company has a market cap of $71.34 million, a PE ratio of -2.54 and a beta of 0.82. The business has a 50-day simple moving average of $2.63 and a 200 day simple moving average of $2.83. XBiotech Inc. has a 52 week low of $2.09 and a 52 week high of $7.74.

XBiotech (NASDAQ:XBIT) last announced its quarterly earnings data on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.